Julie Stansel Skinner

US Patent:

20220296695, Sep 22, 2022

Filed:

Dec 17, 2019

Appl. No.:

17/312442

Inventors:

Chitrananda ABEYGUNAWARDANA - North Wales PA, US
Yadong Adam CUI - North Wales PA, US
Romulo FERRERO - North Wales PA, US
Jian HE - West Point PA, US
Luwy MUSEY - North Wales PA, US
Tanaz PETIGARA - North Wales PA, US
Julie M. SKINNER - West Point PA, US
- Rahway NJ, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

A61K 39/09
A61K 47/20
A61P 31/04
A61P 37/04

Abstract:

The invention is related to multivalent immunogenic compositions comprising more than one polysaccharide protein conjugates, wherein each of the conjugates comprises a polysaccharide from an serotype conjugated to a carrier protein, wherein the serotypes of are as defined herein. In some embodiments, at least one of the polysaccharide protein conjugates is formed by a conjugation reaction comprising an aprotic solvent. In further embodiments, each of the polysaccharide protein conjugates is formed by a conjugation reaction comprising an aprotic solvent. Also provided are methods for inducing a protective immune response in a human patient comprising administering the multivalent immunogenic compositions of the invention to the patient. The multivalent immunogenic compositions are useful for providing protection against infection and/or pneumococcal diseases caused by The compositions of the invention are also useful as part of treatment regimes that provide complementary protection for patients that have been vaccinated with a multivalent vaccine indicated for the prevention of pneumococcal disease.

US Patent:

20220218812, Jul 14, 2022

Filed:

Jun 1, 2020

Appl. No.:

17/614876

Inventors:

- Rahway NJ, US
Robin M. Kaufhold - Lansdale PA, US
Julie M. Skinner - Phoenixville PA, US
Jinfu Xie - Haveford PA, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

A61K 39/09
A61P 31/04
A61K 47/64

Abstract:

The present invention provides methods for treating patients by administering an immunogenic multivalent pneumococcal polysaccharide-protein conjugate vaccine which comprises a serotype 35B polysaccharide-protein conjugate, does not comprise a serotype 29 polysaccharide-protein conjugate, and provides protection against serotype 29.

US Patent:

20230107713, Apr 6, 2023

Filed:

Sep 22, 2022

Appl. No.:

17/934396

Inventors:

- Rahway NJ, US
Chitrananda Abeygunawardana - Ambler PA, US
Luwy Kavuka Musey - Blue Bell PA, US
Michael J. Kosinski - Souderton PA, US
Yadong Adam Cui - Norristown PA, US
Julie Marie Skinner - Phoenixville PA, US

Assignee:

Merck Sharp & Dohme LLC - Rahway NJ

International Classification:

A61K 39/09
A61K 39/39
A61K 47/42

Abstract:

The present invention provides capsular polysaccharides from serotypes identified using NMR The present invention further provides polysaccharide-protein conjugates in which capsular polysaccharides from one or more of these serotypes are conjugated to a carrier protein such as CRM197. Polysaccharide-protein conjugates from one or more of these serotypes may be included in multivalent pneumococcal conjugate vaccines having polysaccharides from multiple additional serotypes.

US Patent:

20230094548, Mar 30, 2023

Filed:

Sep 27, 2022

Appl. No.:

17/935856

Inventors:

- Rahway NJ, US
Chitrananda Abeygunawardana - Ambler PA, US
Luwy Kavuka Musey - Blue Bell PA, US
Michael J. Kosinski - Souderton PA, US
Yadong Adam Cui - Norristown PA, US
Julie Marie Skinner - Phoenixville PA, US

Assignee:

Merck Sharp & Dohme LLC - Rahway NJ

International Classification:

A61K 39/09
A61K 39/39
A61K 47/42

Abstract:

The present invention provides capsular polysaccharides from serotypes identified using NMR. The present invention further provides polysaccharide-protein conjugates in which capsular polysaccharides from one or more of these serotypes are conjugated to a carrier protein such as CRM197. Polysaccharide-protein conjugates from one or more of these serotypes may be included in multivalent pneumococcal conjugate vaccines having polysaccharides from multiple additional serotypes.

US Patent:

20230075760, Mar 9, 2023

Filed:

Sep 22, 2022

Appl. No.:

17/934379

Inventors:

- Rahway NJ, US
Chitrananda Abeygunawardana - Ambler PA, US
Luwy Kavuka Musey - Blue Bell PA, US
Michael J. Kosinski - Souderton PA, US
Yadong Adam Cui - Norristown PA, US
Julie Marie Skinner - Phoenixville PA, US

Assignee:

Merck Sharp & Dohme LLC - Rahway NJ

International Classification:

A61K 39/09
A61K 39/39
A61K 47/42

Abstract:

The present invention provides capsular polysaccharides from serotypes identified using NMR. The present invention further provides polysaccharide-protein conjugates in which capsular polysaccharides from one or more of these serotypes are conjugated to a carrier protein such as CRM197. Polysaccharide-protein conjugates from one or more of these serotypes may be included in multivalent pneumococcal conjugate vaccines having polysaccharides from multiple additional serotypes.

US Patent:

20230041441, Feb 9, 2023

Filed:

Sep 27, 2022

Appl. No.:

17/935864

Inventors:

- Rahway NJ, US
Chitrananda Abeygunawardana - Ambler PA, US
Luwy Kavuka Musey - Blue Bell PA, US
Michael J. Kosinski - Souderton PA, US
Yadong Adam Cui - Norristown PA, US
Julie Marie Skinner - Phoenixville PA, US

Assignee:

Merck Sharp & Dohme LLC - Rahway NJ

International Classification:

A61K 39/09
A61K 39/39
A61K 47/42

Abstract:

The present invention provides capsular polysaccharides from serotypes identified using NMR. The present invention further provides polysaccharide-protein conjugates in which capsular polysaccharides from one or more of these serotypes are conjugated to a carrier protein such as CRM197. Polysaccharide-protein conjugates from one or more of these serotypes may be included in multivalent pneumococcal conjugate vaccines having polysaccharides from multiple additional serotypes.

US Patent:

20230029424, Jan 26, 2023

Filed:

Sep 27, 2022

Appl. No.:

17/935871

Inventors:

- Rahway NJ, US
Chitrananda Abeygunawardana - Ambler PA, US
Luwy Kavuka Musey - Blue Bell PA, US
Michael J. Kosinski - Souderton PA, US
Yadong Adam Cui - Norristown PA, US
Julie Marie Skinner - Phoenixville PA, US

Assignee:

Merck Sharp & Dohme LLC - Rahway NJ

International Classification:

A61K 39/09
A61K 39/39
A61K 47/42

Abstract:

The present invention provides capsular polysaccharides from serotypes identified using NMR. The present invention further provides polysaccharide-protein conjugates in which capsular polysaccharides from one or more of these serotypes are conjugated to a carrier protein such as CRM197. Polysaccharide-protein conjugates from one or more of these serotypes may be included in multivalent pneumococcal conjugate vaccines having polysaccharides from multiple additional serotypes.

US Patent:

20210379174, Dec 9, 2021

Filed:

Jul 13, 2021

Appl. No.:

17/374424

Inventors:

- Rahway NJ, US
Patrick McHugh - Pipersville PA, US
Michael A. Winters - Doylestown PA, US
Julie M. Skinner - Phoenixville PA, US
Jian He - Blue Bell PA, US
Luwy Musey - Blue Bell PA, US
Chitrananda Abeygunawardana - Ambler PA, US
Yadong Adam Cui - Norristown PA, US
Michael J. Kosinski - Souderton PA, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

A61K 39/09
A61K 39/385
A61K 39/145
A61P 31/04
A61K 39/116
A61K 47/02
A61K 47/10
A61K 47/22

Abstract:

The invention is related to multivalent immunogenic compositions comprising more than one polysaccharide protein conjugates, wherein each of the conjugates comprises a polysaccharide from an serotype conjugated to a carrier protein, wherein the serotypes of are as defined herein. In some embodiments, at least one of the polysaccharide protein conjugates is formed by a conjugation reaction comprising an aprotic solvent. In further embodiments, each of the polysaccharide protein conjugates is formed by a conjugation reaction comprising an aprotic solvent. Also provided are methods for inducing a protective immune response in a human patient comprising administering the multivalent immunogenic compositions of the invention to the patient. The multivalent immunogenic compositions are useful for providing protection against infection and diseases caused by . The compositions of the invention are also useful as part of treatment regimes that provide complementary protection for patients that have been vaccinated with a multivalent vaccine indicated for the prevention of pneumococcal disease.